Education
About Us
Working with TipRanks
Follow Us
Recursion Pharmaceuticals (RXRX)
NASDAQ:RXRX
RXRX Stock Chart & Stats
$3.98
-$0.34(-4.54%)
At close: 4:00 PM EST
$3.98
-$0.34(-4.54%)
Day’s Range― - ―
52-Week Range$3.54 - $12.36
Previous CloseN/A
Volume5.68M
Average Volume (3M)20.15M
Market Cap
$2.07B
Enterprise Value$1.02B
Total Cash (Recent Filing)$659.84M
Total Debt (Recent Filing)$82.37M
Price to Earnings (P/E)―
Beta3.38
Next Earnings
Mar 04, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding514,190,250
10 Day Avg. Volume22,122,091
30 Day Avg. Volume20,147,903
Financial Highlights & Ratios
PEG Ratio-0.57
Price to Book (P/B)1.79
Price to Sales (P/S)31.50
P/FCF Ratio-4.97
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue23.38
Enterprise Value/Gross Profit-24.92
Enterprise Value/Ebitda-1.60
Forecast
1Y Price Target
$7.75Price Target Upside94.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyTUPELO study data for REC-4881 showing durable reductions in polyp burden support the drug's potential for registrational study and a larger addressable patient population.
Financial RunwayStrengthened cash position and milestone agreements improve financial runway and reduce near-term funding pressure, supporting continued pipeline development through 2027.
Platform Validation And PartnershipsClinical results combined with pharmaceutical collaborations validate the AI-driven discovery platform and enhance commercialization prospects through milestone-linked partnerships.
Bears Say
Regulatory UncertaintyDebate over the optimal registrational path and reliance on FDA feedback creates regulatory uncertainty that could delay development timelines.
Safety ProfileREC-4881 exhibited toxicities consistent with MEK inhibitors, which will necessitate mitigation strategies and could complicate broader clinical development.
Tolerability And Adherence RiskExpanding enrollment to a younger population raises concerns about discontinuation and dose interruptions that could affect efficacy readouts and trial retention.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $3.54 and its highest was $12.36 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $2.07B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 23 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Nov 05, 2025. The company reported -$0.36 earnings per share for the quarter, beating the consensus estimate of -$0.377 by $0.017.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.3.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 514,190,250 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.36 in its last earnings report, beating expectations of -$0.377. Following the earnings report the stock price went down -0.8%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.75 (94.72% Upside)
$7.75 (94.72% Upside)
Blogger Sentiment
Bullish
RXRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 556.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.3%
Last 30 Days ▼ 5.3%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.02%
12-Months-Change
Fundamentals
Return on Equity
-91.06%
Trailing 12-Months
Asset Growth
92.64%
Trailing 12-Months
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook with strong leadership transitions, a robust financial position, and significant achievements in partnerships and platform development. However, there are challenges related to drug safety and clinical uncertainty that require careful management.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$7.75
▲(94.72% Upside)
Technical Analysis
Agios Pharma
―
Galapagos
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
2.45% Insiders
10.52% Mutual Funds
0.07% Other Institutional Investors
63.93% Public Companies and Individual Investors